Skip to main content

CORRECTION article

Front. Allergy
Sec. Therapies and Therapeutic Targets
Volume 6 - 2025 | doi: 10.3389/falgy.2025.1557356

Corrigendum A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema

Provisionally accepted
Dan Sexton Dan Sexton 1Ryan Faucette Ryan Faucette 1Melody Rivera-Hernandez Melody Rivera-Hernandez 1Jon A. Kenniston Jon A. Kenniston 1Nikolaos Papaioannou Nikolaos Papaioannou 1Janja Cosic Janja Cosic 1Kris Kopacz Kris Kopacz 1Gary Salmon Gary Salmon 2Chantal Beauchemin Chantal Beauchemin 1Salomé Juethner Salomé Juethner 3Dave Yeung Dave Yeung 1*
  • 1 Takeda Development Center Americas, Inc., Cambridge, United States
  • 2 Charles River Laboratories, Harlow, England, United Kingdom
  • 3 Takeda Pharmaceuticals USA, Inc., Lexington, United States

This article is a correction to:

  1. A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema

    1. Read original article

The final, formatted version of the article will be published soon.

    Incorrect Copyright StatementIn the published article, there was an error in the Copyright statement. The statement was incorrectly written as “Copyright © 2024 Sexton, Faucette, Rivera-Hernandez, Kenniston, Papaioannou, Cosic, Kopacz, Salmon, Beauchemin, Juethner and Yeung”. The corrected statement is “Copyright © 2024 Takeda Pharmaceuticals USA, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.”The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

    Keywords: biomarkers, phage display, Bradykinin, Plasma Kallikrein, hereditary angioedema

    Received: 08 Jan 2025; Accepted: 23 Jan 2025.

    Copyright: © 2025 Sexton, Faucette, Rivera-Hernandez, Kenniston, Papaioannou, Cosic, Kopacz, Salmon, Beauchemin, Juethner and Yeung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Dave Yeung, Takeda Development Center Americas, Inc., Cambridge, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.